US Supreme Court Rejects CareDx Appeal in False Advertising Case Against Natera

The US Supreme Court has rejected CareDx's appeal in a false advertising lawsuit against Natera, effectively upholding the lower court's ruling in favor of Natera. CareDx had alleged that Natera made misleading claims about competing products. The case concerns competition in the post-transplant monitoring test market. CareDx argued that Natera's advertisements harmed its products, but the court found Natera's claims were not misleading. The Supreme Court's denial of the appeal is seen as a significant legal victory for Natera, potentially strengthening its market position and setting a precedent for similar cases. With the rejection of CareDx's appeal, the case concludes with the lower court's decision. Natera has thus been cleared of the false advertising allegations. This is not investment advice.